Cargando…

Liposomes are Poorly Absorbed via Lung Lymph After Inhaled Administration in Sheep

Enhancing the delivery of therapeutic agents to the lung lymph, including drugs, transfection agents, vaccine antigens and vectors, has the potential to significantly improve the treatment and prevention of a range of lung-related illnesses. One way in which lymphatic delivery can be optimized is vi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibrahim, Jibriil P, Haque, Shadabul, Bischof, Robert J, Whittaker, Andrew K, Whittaker, Michael R, Kaminskas, Lisa M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201389/
https://www.ncbi.nlm.nih.gov/pubmed/35721215
http://dx.doi.org/10.3389/fphar.2022.880448
_version_ 1784728304298754048
author Ibrahim, Jibriil P
Haque, Shadabul
Bischof, Robert J
Whittaker, Andrew K
Whittaker, Michael R
Kaminskas, Lisa M
author_facet Ibrahim, Jibriil P
Haque, Shadabul
Bischof, Robert J
Whittaker, Andrew K
Whittaker, Michael R
Kaminskas, Lisa M
author_sort Ibrahim, Jibriil P
collection PubMed
description Enhancing the delivery of therapeutic agents to the lung lymph, including drugs, transfection agents, vaccine antigens and vectors, has the potential to significantly improve the treatment and prevention of a range of lung-related illnesses. One way in which lymphatic delivery can be optimized is via the use of nanomaterial-based carriers, such as liposomes. After inhaled delivery however, there is conflicting information in the literature regarding whether nanomaterials can sufficiently access the lung lymphatics to have a therapeutic benefit, in large part due to a lack of reliable quantitative pharmacokinetic data. The aim of this work was to quantitatively evaluate the pulmonary lymphatic pharmacokinetics of a model nanomaterial-based drug delivery system (HSPC liposomes) in caudal mediastinal lymph duct cannulated sheep after nebulized administration to the lungs. Liposomes were labelled with (3)H-phosphatidylcholine to facilitate evaluation of pharmacokinetics and biodistribution in biological samples. While nanomaterials administered to the lungs may access the lymphatics via direct absorption from the airways or after initial uptake by alveolar macrophages, only 0.3 and 0.001% of the (3)H-lipid dose was recovered in lung lymph fluid and lymph cell pellets (containing immune cells) respectively over 5 days. This suggests limited lymphatic access of liposomes, despite apparent pulmonary bioavailability of the (3)H-lipid being approximately 17%, likely a result of absorption of liberated (3)H-lipid after breakdown of the liposome in the presence of lung surfactant. Similarly, biodistribution of (3)H in the mediastinal lymph node was insignificant after 5 days. These data suggest that liposomes, that are normally absorbed via the lymphatics after interstitial administration, do not access the lung lymphatics after inhaled administration. Alternate approaches to maximize the lung lymphatic delivery of drugs and other therapeutics need to be identified.
format Online
Article
Text
id pubmed-9201389
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92013892022-06-17 Liposomes are Poorly Absorbed via Lung Lymph After Inhaled Administration in Sheep Ibrahim, Jibriil P Haque, Shadabul Bischof, Robert J Whittaker, Andrew K Whittaker, Michael R Kaminskas, Lisa M Front Pharmacol Pharmacology Enhancing the delivery of therapeutic agents to the lung lymph, including drugs, transfection agents, vaccine antigens and vectors, has the potential to significantly improve the treatment and prevention of a range of lung-related illnesses. One way in which lymphatic delivery can be optimized is via the use of nanomaterial-based carriers, such as liposomes. After inhaled delivery however, there is conflicting information in the literature regarding whether nanomaterials can sufficiently access the lung lymphatics to have a therapeutic benefit, in large part due to a lack of reliable quantitative pharmacokinetic data. The aim of this work was to quantitatively evaluate the pulmonary lymphatic pharmacokinetics of a model nanomaterial-based drug delivery system (HSPC liposomes) in caudal mediastinal lymph duct cannulated sheep after nebulized administration to the lungs. Liposomes were labelled with (3)H-phosphatidylcholine to facilitate evaluation of pharmacokinetics and biodistribution in biological samples. While nanomaterials administered to the lungs may access the lymphatics via direct absorption from the airways or after initial uptake by alveolar macrophages, only 0.3 and 0.001% of the (3)H-lipid dose was recovered in lung lymph fluid and lymph cell pellets (containing immune cells) respectively over 5 days. This suggests limited lymphatic access of liposomes, despite apparent pulmonary bioavailability of the (3)H-lipid being approximately 17%, likely a result of absorption of liberated (3)H-lipid after breakdown of the liposome in the presence of lung surfactant. Similarly, biodistribution of (3)H in the mediastinal lymph node was insignificant after 5 days. These data suggest that liposomes, that are normally absorbed via the lymphatics after interstitial administration, do not access the lung lymphatics after inhaled administration. Alternate approaches to maximize the lung lymphatic delivery of drugs and other therapeutics need to be identified. Frontiers Media S.A. 2022-06-02 /pmc/articles/PMC9201389/ /pubmed/35721215 http://dx.doi.org/10.3389/fphar.2022.880448 Text en Copyright © 2022 Ibrahim, Haque, Bischof, Whittaker, Whittaker and Kaminskas. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Ibrahim, Jibriil P
Haque, Shadabul
Bischof, Robert J
Whittaker, Andrew K
Whittaker, Michael R
Kaminskas, Lisa M
Liposomes are Poorly Absorbed via Lung Lymph After Inhaled Administration in Sheep
title Liposomes are Poorly Absorbed via Lung Lymph After Inhaled Administration in Sheep
title_full Liposomes are Poorly Absorbed via Lung Lymph After Inhaled Administration in Sheep
title_fullStr Liposomes are Poorly Absorbed via Lung Lymph After Inhaled Administration in Sheep
title_full_unstemmed Liposomes are Poorly Absorbed via Lung Lymph After Inhaled Administration in Sheep
title_short Liposomes are Poorly Absorbed via Lung Lymph After Inhaled Administration in Sheep
title_sort liposomes are poorly absorbed via lung lymph after inhaled administration in sheep
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201389/
https://www.ncbi.nlm.nih.gov/pubmed/35721215
http://dx.doi.org/10.3389/fphar.2022.880448
work_keys_str_mv AT ibrahimjibriilp liposomesarepoorlyabsorbedvialunglymphafterinhaledadministrationinsheep
AT haqueshadabul liposomesarepoorlyabsorbedvialunglymphafterinhaledadministrationinsheep
AT bischofrobertj liposomesarepoorlyabsorbedvialunglymphafterinhaledadministrationinsheep
AT whittakerandrewk liposomesarepoorlyabsorbedvialunglymphafterinhaledadministrationinsheep
AT whittakermichaelr liposomesarepoorlyabsorbedvialunglymphafterinhaledadministrationinsheep
AT kaminskaslisam liposomesarepoorlyabsorbedvialunglymphafterinhaledadministrationinsheep